Twitxy Saved

iOrganBio

Verified account This account is verified. Learn more

@iOrganBio

The Right Cells. Consistently. At Scale.
Chapel Hill, NC iorgan.bio Joined July 2025
51 Following 44 Followers 71 Posts

Latest posts 5

Pinned post

iOrganBio Verified account @iOrganBio
🚧 The status quo of biological model discovery, development, and biomanufacturing is blocking progress on some of humanity’s greatest biomedical breakthroughs.

At iOrganBio, we’re re-designing cell model discovery and manufacturing from the ground up, leveraging modern automation and machine learning as fundamental components of our system. Using rapid turnaround scRNA-seq, we are able to digitize cell state and automatically guide stem cell differentiation towards bioequivalency using in vivo cell states as a blueprint.

Our platform unlocks the next stage of biotechnological development, treating cells as the complex and dynamic systems that we’ve always known them to be. Join us as we transform the way we use cells to cure disease and forge progress using The Right Cells, Consistently, At Scale.

🌐 Learn more about our tech at iorgan.bio
✉️ To start a collaboration with iOB, email partnering@iorgan.bio
2:39
1 replies 2 reposts 9 likes 2.8K views View on X
iOrganBio Verified account @iOrganBio
“We are excited to partner with iORGANBIO in contributing to greater efficiency in drug discovery and advancements in cell therapy and regenerative medicine. This new partnership will directly support Mitsui Chemicals’ aim to create new solutions that support life, health and enriched lifestyles,” said Shunsuke Fujii, PhD, General Manager at Mitsui Chemicals.

Following last week’s news, we’re excited to share more about our collaboration with Mitsui Chemicals.

Mitsui Chemicals brings more than a century of materials science and innovative chemical formulations, including its InnoCell™ cell culture plates. Their highly oxygen-permeable design supports healthier, longer-lasting cultures and more uniform 3D tissues, including iPSC-derived organoids.

iOrganBio brings an integrated Physical AI platform built to develop and manufacture consistent human cells at scale. CellHorizon defines the target cell state, while CellDiscovery rapidly explores the experimental design space to find the conditions that reach it. CellTelemetry digitizes every manufactured cell, giving our adaptive manufacturing platform, CellForge, the real-time insight it needs to deliver consistent cells, batch after batch.

Together, we aim to:
📷 Enable cell types and complex organoids that have been difficult to manufacture
📷 Control culture conditions to improve the quality and consistency of human cells and organoids
📷 Explore new drug discovery technologies, including efficacy and safety testing, that could complement or replace animal testing
📷 Develop new materials and methods to dynamically interact with cells and precisely guide their behavior
Read the full press release here: globenewswire.com/news-release/2…
www.globenewswire.com iORGANBIO and Mitsui Chemicals Collaborate to Advance AI-Driven Human Cell and Organoid Manufactu... iORGANBIO and Mitsui Chemicals Collaborate to Advance AI-Driven Human Cell and Organoid Manufacturing...
iOrganBio Verified account @iOrganBio
Excited to present three posters at the #ISSCR Disease Modeling & Drug Discovery Symposium, Dec 16–18 in San Diego! Come find us at the poster sessions to see how CellForge™ and CellDiscovery™ are making stem-cell manufacturing adaptive.
iOrganBio Verified account @iOrganBio
We’re honored to announce an investment from Mitsui Chemicals Group through 321Catalyst Ventures!

In our new collaboration, we’ll pair InnoCell™ plates with our AI-driven, closed-loop platform to make more consistent human cells and organoids for drug screening.
iOrganBio Verified account @iOrganBio
🚀 The launch of NIH’s Office of Research Innovation, Validation, and Application (ORIVA) is a major milestone for the non-animal methods (NAMs) ecosystem.

By coordinating NIH-wide efforts to develop, validate, and scale human-based research approaches—and by supporting funding, training, and regulatory translation—ORIVA signals a meaningful shift toward models that are more human-relevant, translatable, and fit for modern biomedical research.

At @iOrganBio, we see this as strong momentum for the future of precision cell manufacturing and human-based model systems. As the NAMs ecosystem grows, our focus remains on building reproducible, high-fidelity human cell systems and the data infrastructure needed to make them useful for discovery, disease modeling, and translational research.

📄 Read more about ORIVA at dpcpsi.nih.gov/oriva
🌐 Learn more about iOB at iorgan.bio